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ABSTRACT
MODIFICATIONS OF MYOFILAMENT STRUCTURE AND FUNCTION DURING
GLOBAL MYOCARDIAL ISCHEMIA
SEPTEMBER 2016
MIKE K. WOODWARD, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., CANDIDATE, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Edward P. Debold

Cardiac arrest is a prevalent condition with a poor prognosis, attributable in part
to persistent myocardial dysfunction following resuscitation. The molecular basis of this
dysfunction remains unclear. We induced cardiac arrest in a porcine model of acute
sudden death and assessed the impact of ischemia and reperfusion on the molecular
function of isolated cardiac contractile proteins. Cardiac arrest was electrically induced,
left untreated for 12 min, and followed by a resuscitation protocol. With successful
resuscitations, the heart was reperfused for 2 h (IR2) and the muscle harvested. In failed
resuscitations, tissue samples were taken following the failed efforts (IDNR). Actin
filament velocity, using myosin isolated from IR2 or IDNR cardiac tissue, was nearly
identical to myosin from the control tissue in a motility assay. However, both maximal
velocity (25% faster than control) and Ca2+ sensitivity (pCa50 6.57 ± 0.04 IDNR vs. 6.34
± 0.07 control) were significantly (p < 0.05) enhanced using native thin filaments (actin,
troponin, and tropomyosin) from IDNR samples, suggesting that the enhanced velocity is
mediated through an alteration in muscle regulatory proteins (troponin and tropomyosin).
Mass spectrometry analysis showed that only samples from the IR2 had an increase in
total phosphorylation levels of troponin (Tn) and tropomyosin (Tm), but both IR2 and
IDNR samples demonstrated a significant shift from mono-phosphorylated to bisiv

phosphorylated forms of the inhibitory subunit of Tn (TnI) compared to control. This
suggests that the shift to bis-phosphorylation of TnI is associated with the enhanced
function in IDNR, but this effect may be attenuated when phosphorylation of Tm is
increased in tandem, as was observed for IR2. There are likely many other molecular
changes induced following cardiac arrest, but to our knowledge, these data provide the
first evidence that this form cardiac arrest can alter the in vitro function of the cardiac
contractile proteins.
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CHAPTER I
INTRODUCTION
Research must be conducted to discover a molecular basis for the myocardial
dysfunction that occurs due to global ischemia. Sudden cardiac arrest is typically
precipitated by ventricular fibrillation or pulseless ventricular tachycardia, a lifethreatening condition characterized by an abrupt loss of blood flow resulting in
progressive global ischemia [Neumar et al., 2008]. The earliest biochemical changes that
occur in the myocytes during an ischemic event are the accumulation of metabolites
including: hydrogen ions (H+), inorganic phosphate (Pi), and adenosine diphosphate
(ADP) [Bolli and Marban, 1999 , Allen and Orchard, 1987 , Schaefer et al., 1990 ,
Elliot et al., 1992]. These molecules exert direct depressive effects on the mechanical
function of the contractile apparatus, however levels of these molecules quickly (< 5
minutes) return to normal with return of blood flow and therefore cannot explain the
persistent decrease in cardiac function [Bolli and Marban, 1999 , Allen and Orchard,
1987 , Schaefer et al., 1990 , Elliot et al., 1992]. At a molecular level, force and
power in the heart result from the calcium (Ca2+) dependent sliding of actin-based thin
filaments past myosin-thick filaments in a process driven by the hydrolysis of adenosine
triphosphate (ATP). Thus, the more likely cause of post-arrest myocardial dysfunction
are the persistent structural modifications of the contractile apparatus similar to those
which occur in models of localized ischemia [Rao et al., 2007]. Several forms of changes
have been seen including but not limited to: the contractile proteins incurring oxidative
damage [Tiago et al., 2006 , Alvarez and Radi., 2003 , Dean et al., 1997], posttranslational modifications [Rao et al., 2007 , Han and Ogut, 2010 , Han and Ogut,
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2011 , Christopher et al., 2009], or degradation by proteases [Dean et al., 1997 ,
Sawicki et al., 2005 , Day et al., 2007] as a result of ischemia.
Successful resuscitation with return of spontaneous circulation (ROSC) can
restore blood flow to near normal levels within minutes of an event, however the
prognosis for revived patients remains quite poor with only ~10 % surviving to hospital
discharge if it occurs outside of a hospital [Eisenberg and Mengert, 2001 ,
Schoenenberger et al., 1994] and only improves to 23% if it occurs in a hospital setting
[Roger et al., 2012]. After resuscitation many patients experience “postcardiac arrest
syndrome,” characterized by a persistent mechanical myocardial dysfunction in the
absence of large morphological changes [Kern, 2002], which is believed to be a leading
cause of the high morbidity and mortality following cardiac arrest [Neumar et al., 2008].
The most notable structural changes that have been observed include post-translational
modifications to myosin and troponin subunit I (TnI), such as cleavage, oxidative
damage, or phosphorylation, which may have resulted in the marked decrease in
contractile function [Monasky et al., 2011 , Rao et al., 2007].
In both research and clinical settings the serum levels of TnT (the subunit that
interacts with tropomyosin (Tm)) and TnI can also be measured to determine the severity
of myocardial damage and necrosis that caused the release of Tn into the serum [Scheitz
et al., 2011 , Park et al., 2011 , Lotze et al., 2011]. However the molecular basis of
the persistent mechanical dysfunction are unclear and thus the extremely poor prognosis
is unclear [Chalkias and Xanthos, 2012 , Bolli and Marban, 1999]. For example it is
unknown if cardiac arrest directly affects the function of contractile proteins that give rise
to the force and power generating capacity of the heart [Chalkias and Xanthos, 2012].

2

This induced global ischemia closely mirrors a clinical setting where human
patients whose heart contractions have ceased and have been revived before arriving at
the hospital. These patients still have decreased contractile function post
resuscitation/reperfusion and high mortality rates. Therefore this work could have
important implications for understanding the molecular basis for this highly prevalent
condition. These types of investigations could provide crucial insight for the development
of novel treatments for this deadly condition.
Specific Aims
The goal of this study was to determine the effect of ischemia and ischemiareperfusion injury on the function of contractile proteins that help explain the long term
depression in cardiac function following these types of events. A more effective
understanding of the molecular basis for the depressed cardiac function could potentially
lead to improvements in understanding how to improve human heart health. We
hypothesized that the isolated cardiac myosin from post-ischemia-reperfusion animals
would have a decreased ability to translocate actin filaments and that this would be in
part attributable to effects on myosin. Also native thin filaments (NTF), composed of
actin and the regulatory proteins Tn and Tm, were isolated and examined since previous
studies implicated regulatory protein damage (cleavage and post-translational
modifications). We also hypothesized that if there were any alterations (cleavage or
phosphorylation) to these regulatory proteins, then it would result in an altered response
to Ca2+ and would likely result in decreased contractility.
To accomplish these goals we isolated the myosin and NTF from cardiac tissue
samples and used the in vitro motility assay to determine if there was any change in
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function compared to control (hearts that did not undergo ischemia and/or reperfusion).
The in vitro motility assay allowed us to view actin filaments and NTF as they
translocated over a bed of isolated cardiac myosin and flow-cell conditions were altered
to examine their impact. This allowed us to analyze the velocity, determine a change in
contractile function, and infer a mechanistic change that could have resulted in the altered
function. Also specific gel electrophoresis techniques were attempted to determine if
there were changes in the phosphorylation status of certain proteins or if cleavage had
occurred. These results were inconclusive and so we employed electrospray ionization
liquid chromatography tandem mass spectrometry to gain much more accurate data on
changes in phosphorylation and cleavage.
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CHAPTER II
LITERATURE REVIEW
Calcium and Actomyosin Interaction
Cardiac muscle is able to produce force because of the cyclical interaction of actin
and myosin, the two key contractile proteins. Myosin is a molecular motor which can
bind to actin and hydrolyze ATP to produce mechanical force or generate motion. Figure
1 displays how the binding of ATP, binding of actin, and hydrolysis follow a cyclic
interaction allowing for myosin to bind, produce force, and release from actin to reinitiate
the cycle. The displacement caused by myosin’s power-stroke thus causes the thick and
thin filament to slide over each other, which causes the contraction of muscle tissue.

Figure 1. The Crossbridge Cycle. A schematic representation of the crossbridge cycle
with d as the displacement and ton as the duration that the myosin is strongly bound to
actin, which is composed of tADP and trigor. The duration of time the cycle when ADP
bound myosin is bound to actin is tADP. trigor is the time at which actin and myosin are
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strongly bound in rigor awaiting the binding of ATP to allow the release of myosin from
actin. Originally from [Debold et al., 2011].

This interaction is closely regulated in a Ca2+ dependent manner through Ca2+
interacting with Tn, regulating the position of Tm on actin [Ebashi and Endo, 1968 ,
Gordon et al., 2000 , Heeley, 1994]. Figure 2 illustrates how Tn unbound to Ca2+ holds
Tm in a position that prevents strong stereo-specific binding of myosin to actin. Ca2+
binds to the TnC subunit and exposes a hydrophobic section of its N-terminus. This
hydrophobic pocket then allows the switch domain of TnI (the inhibitory subunit) to bind,
which allows Tm to move into the actin helix groove ultimately causing Tm to unblock
the myosin binding sites on actin.

Figure 2. Troponin conformation at low [Ca2+] and high [Ca2+]. The conformational
change that occurs in TnC and TnI’s C-terminal tail, which allows Tm to move into the
groove of the actin-helix and thus opens the myosin binding sites on actin. The heart
cycles between: A) low [Ca2+] in diastole and B) high [Ca2+] in systole. Originally from
[Day et al., 2007].
6

Figure 3. Tropomyosin and the actin filament. Skeletal muscle thin filament: A) only
actin, B) with no Ca2+, C) with Ca2+, and D) decorated with myosin S1. The light green
areas are weak myosin binding sites, the red areas are strong myosin binding sites, and
the dark filament parallel to the gray actin strand is the Tm. Originally from [Gordon et
al., 2001].

In Figure 3B there is no Ca2+ able to bind Tn and thus Tm remains and prevents
access to the myosin binding sites, but with a high Ca2+ state [Fig 3C] Tm moves away
from actin’s myosin binding sites. Decoration with myosin S1 [Fig 3D] however,
demonstrates that with the binding of myosin S1 heads that there is an even greater
movement of Tm farther away from the myosin binding sites. This implies a 3 state
model that suggests Tm position is modulated by Tn, Ca2+ binding, as well as myosin
binding. A blocked state in which there is low [Ca2+] and myosin cannot bind, but upon
Ca2+ binding TnC the Tm is no longer strongly held blocking myosin binding sites (called
7

the closed state) and so a myosin head is able to bind. Once in the closed state and a
myosin head is able to bind, it prevents the Tm from blocking adjacent sites, which
allows more myosin to bind and propagate this open state across the filament. Proper
Ca2+ dependent regulation is necessary for normal contraction of both skeletal and
cardiac muscle. This is especially crucial in the heart where efficient pumping of the
blood requires the careful coordination of systole (ventricular contraction/ejection) and
diastole (relaxation/filling).
During acute myocardial ischemia there are a host of intracellular changes
including the accumulation of H+ that affect the contractile process. Myocardial ischemia
is a partial or complete reduction of blood flow to cardiac muscle tissues, which deprives
the muscle cells of the substrates necessary for energy production but also causes the
build-up of cellular metabolites [Allen and Orchard, 1987]. During ischemia, ATP
production through oxidative phosphorylation stops, causing a build-up of phosphate
products (metabolites), which can lead to arrhythmias and a decrease in tension
production [Allen and Orchard, 1987]. This can only be remedied if there is an increase
of ATP generation by the re-initiation of oxidative phosphorylation or a decrease in ATP
usage, although it is the H+ and Pi, not the reduced ATP that causes reduced contractility
[Allen and Orchard, 1987].
Myocardial ischemia for more than one hour can lead to permanent damage, but
reperfusion, the restoration of blood flow to the tissues, can actually accelerate the
damage [Allen and Orchard, 1987]. Reperfusion is not a perfect solution to ischemia,
although if the tissue is reperfused before or during the early ischemic contracture then
normal pressure is completely restored [Allen and Orchard, 1987]. However, if the tissue
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is reperfused long after the ischemic contracture has occurred, then the pressure does not
recover and can lead to cell damage advancement and the subsequent release of
intracellular contents [Allen and Orchard, 1987]. This is deemed reperfusion damage,
which occurs because Ca2+ is returned to the tissues after a period with low Ca2+ levels
and this sudden accumulation can cause cellular damage.
There are several theories as to the etiology of the reduced contractility from an
ischemic attack, which range from issues with action potential generation, incorrect Ca2+
delivery to the contractile proteins, or some alteration and damage to the proteins
themselves [Allen and Orchard, 1987]. Each is likely partially responsible for the
reduced function. A covalent modification of Tn such as phosphorylation could lead to a
loss of Ca2+ affinity or a competition between Ca2+ and other cations [Allen and Orchard,
1987]. Porcine and murine (rats and mice) models of injury incurred from ischemia and
reperfusion have displayed possible proteolytic cleavages (especially of TnI),
phosphorylation of myosin and the regulatory proteins, and modifications due to reactive
oxygen species [Rao et al., 2007].
Changes in Calcium Sensitivity and Tension
Global ischemia occurs after sudden cardiac arrest, which causes a halt in
myocardial contractions and thus blood circulation ceases as well. During this ischemic
episode, there is reduced supply of necessary nutrients and an accumulation of harmful
metabolites. The changes that occur can be severe and alter the myocardium’s ability to
properly respond to Ca2+ [Fig 4]. In Figure 4C, the tracings were obtained from
reperfused cardiac tissue that has undergone ischemia there is an increase in intracellular
[Ca2+]. Figure 4D shows that force is reduced due a loss of Ca2+ sensitivity, which can be
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seen as a rightwards shift in the force-pCa curve. Although there are differences between
acidosis [Fig 4A , Fig 4B] where there is no difference in intracellular Ca2+ and yet there
is still a large loss in Ca2+ sensitivity and a reduction in force. Also in a failing heart [Fig
4E , Fig 4F] there is actually an increase in Ca2+ sensitivity, which results in a leftwards
shift in the pCa curve. Not all conditions have the same impact on Ca2+ sensitivity, but
each pathology causes detrimental effects on force production and alterations of the
response to Ca2+. As cardiac contractions are precisely controlled events, any alteration to
cardiac Ca2+ sensitivity could severely affect its ability to produce force.

Figure 4. Changes in force-[Ca2+] relationships. A, C, and E are tracings of the force
and cytosolic [Ca2+] in different physiological environments. B, D, and F are the pCaforce relationships. The effect of acidosis is shown in A and B, the effect of ischemia is
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shown in C and D, and the effect of a failing heart is shown in E and F. Originally from
[Day et al., 2007].

One research study applied a low flow ischemia model on porcine hearts,
specifically fibers from the left ventricle supplied by the left anterior descending coronary
artery, which can more effectively simulate ischemia in humans with coronary heart
disease than other animal models. In this study the term “stunned” was used to refer to
post-ischemic myocardium that had depressed contractile function, which could reverse
over a few hours or days. This decreased function was hypothesized to occur because of
decreased Ca2+ sensitivity and so the researchers directly tested if the myofilaments had
reduced post ischemia Ca2+ sensitivity. Using an open-chest in vivo porcine heart model
they obtained biopsies of myocardium before and after ischemia was induced and then
subsequently permeabilized the fibers in order to measure Ca2+ and tension levels. This in
vivo study allowed them to look at subsequent measurements of Ca2+ sensitivity and
tension at different areas of the left ventricle and over the time span of the whole
experiment. It was discovered that maximal Ca2+ activated tension generating ability after
ischemia (2.77 ± 0.51 104 N/m2) did not differ much from the control (2.69 ± 0.27 104
N/m2) [Hofmann et al., 1993]. Also ischemia did appear to have induced a significant
Ca2+ sensitivity reduction as the pCa required for half-maximal activation of tension
decreased from 5.88 ± 0.05 control to 5.69 ± 0.03 post-ischemia [Hofmann et al., 1993].
This decreased sensitivity likely caused reduced velocity and reduced tension generating
ability at low Ca2+ concentration levels.
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Oxidative Damage
There has also been evidence of an increase in nitric oxide, superoxide,
peroxynitrite (ONOO-), and hydroxyl radicals that can cause damage to cells and
especially to the muscle proteins themselves [Rao et al., 2007]. Some of the damage can
be prevented by reducing the toxicity of the radicals or removing the damaged proteins,
although the cell cannot always degrade the damaged proteins and thus their altered or
loss of function remains part of the system [Dean et al., 1997]. When the proteins are
oxidized it often leads to a loss of function or unfolding, which in turn can allow for more
accessibility to proteases [Dean et al., 1997]. Reactive oxygen species (ROS) can
damage macromolecules in many cell types and play key roles in many diseases such as
ischemia. During ischemia there can be an increase in the levels of these damaging
compounds. One such compound called (ONOO-) has been shown to cause protein
modifications and has reduced maximum isometric tension at high concentrations
[Alvarez and Radi, 2003]. It is formed when nitric oxide and superoxide radicals react
and this ONOO- product can permeate biological membranes and act as both a nitrating
agent and an oxidizer [Alvarez and Radi, 2003]. ONOO- can directly interact with amino
acid residues and even produce more free radicals that can continue to cause more protein
alterations. Primarily residues containing sulfur (Cys, Met) or aromatic groups (Trp, Tyr,
Phe, His) are the first to react with these free radicals [Alvarez and Radi, 2003]. Another
study showed that there were velocity reductions for myosin treated with ONOO- and
that this may cause modifications to myosin binding protein-C instead of myosin itself at
10uM [ONOO-] [Snook et al., 2007]. There were also some functional losses due to
actin nitration as well, although bare actin suffered a larger dysfunction compared to
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regulated actin at 10uM and 100uM [ONOO-] [Snook et al., 2007]. This may have been
due to Tm and Tn subunits interfering with ONOO- access to key sites, which was
supported from data displaying that the two proteins showed no nitration at 10uM and
only a slight amount at 100 uM [Snook et al., 2007].
Other damaging compounds such as superoxide and nitric oxide could increase in
prevalence and lead to damage during myocardial ischemia and reperfusion in a murine
model [Liu et al., 1997]. It was discovered that superoxide in tissues of the ischemic
cardiac muscle region were increased by 140%, and nitric oxide levels increased by 90%,
and nitric oxide synthase activity was increase by 212%, while the non-ischemic regions
were unchanged [Liu et al., 1997]. This data displayed that nitric oxide and superoxide
formation were increased after reperfusion of ischemic heart tissue and that they may be
implicated in reperfusion injury.
Nitric oxide production increases during early reperfusion and can react with
superoxide to form the damaging ONOO-, which can lead to protein alterations and a
reduction in function. It has also been seen that adding superoxide dismutase or halting
nitric oxide synthase activity eliminated the nitric oxide increase [Zweier et al., 2001].
Also there was an over two fold recovery of contractile function in hearts treated with
inhibitors of superoxide dismutase or nitric oxide synthase, which displays possible
techniques to reduce these oxidative species [Zweier et al., 2001]. After myocardial
infarction and heart failure nitric oxide synthase is expressed and the more nitric oxide
produced lead to more cardiac dysfunction [Feng et al., 2001]. After myocardial
infarction in mutant mice with knockout nitric oxide synthase expression there were a
lower mortality rate and improved contractility [Feng et al., 2001]. Nitric oxide produced
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by endothelial nitric oxide synthase-3 however has been shown to limit the damage from
ischemia-reperfusion and it has been shown that overexpression of this gene specifically
in cardiomyocytes improved cardiac function [Elrod et al., 2006]
Free radicals can damage cellular macromolecules by highly reactive chain
reactions that involve reactive compounds removing electrons form other molecules and
thus creating more reactive substances [Dean et al., 1997]. In reperfused rabbit hearts
there were increases of semiquinone, reactive oxygen species, a nitrogenated radical, and
hydroxyl radicals that can all be generated in post-ischemic cardiac muscle and could
cause damage [Zweier et al., 1989]. Superoxide dismutase, deferoxamine, and mannitol
were able to reduce the increase of the reactive oxygen species and thus could also be
reasonable strategies to decrease the oxidative damage that can occur [Zweier et al.,
1989]. After ischemia the subsequent reperfusion causes a large release of free oxygen
radicals and expression or addition of superoxide dismutase immediately before
reperfusion reduces the levels to closer to non-reperfused [Grill et al., 1992]. Another
avenue of protection against ischemia-reperfusion damage is the MCP-1 (monocyte
chemoattractant protein-1), which was expressed in transgenic mice after global
ischemia-reperfusion and lead to protection against reactive oxygen species induced
cardiac dysfunction [Morimoto et al., 2008]. In vitro experiments showed that ischemiareperfusion caused an increase in MCP-1 mRNA expression [Morimoto et al., 2008].
Mice with cardiomyocyte specific MCP-1 overexpression stopped superoxide formation
during ischemia-reperfusion and there was higher superoxide dismutase activity in the
transgenic mice than wild type [Morimoto et al., 2008]. These oxidative species can
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cause damage such as nitrosylations, which can be detected by specific gels (Snitrosylated protein detection kit, Cayman Chemical Company, Ann Arbor, Michigan).
Possible Myosin Alterations
It is known that phosphorylation can play a role in regulating myosin activity,
which leads to reason that changes in phosphorylation can alter contractile function
[Alamo et al., 2008]. The phosphorylation of the regulatory light chains can interact
within the same S1 head or between the 2 myosin heads as well [Alamo et al., 2008].
This phosphorylation of the regulatory light chain may reduce the interactions between
the 2 myosin heads, thus allowing myosin to interact with actin and produce contractile
force [Alamo et al., 2008].
One study discovered that in human heart failure due to mitral regurgitation that
there was no change to the actomyosin ATPase activity, contrary to evidence found in
some animal studies [Nguyen et al., 1996]. Tissue samples were obtained from the
anterior segment of the left ventricular subepicardial wall of the hearts and the isolated
myosin was analyzed with in vitro motility assays [Nguyen et al., 1996]. The mean
velocity of the normal left ventricle function tissue was 1.3 ± 0.3 um/s and in the mitral
regurgitation heart failure it was 1.0 ± 0.3 um/s, which was not a significant difference
[Nguyen et al., 1996]. One can infer that the myosin did not have mechanical or ATPase
activity changes from mitral regurgitation heart failure in terms the motion producing
capacity, but this does not prove that there were no physical modifications [Nguyen et al.,
1996].
If cardiomyocytes are pharmacologically preconditioned (with adenosine) in vivo
to protect against further ischemic events there is an increase in phosphorylation of 2 sites
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to myosin light chain 1 (MLC-1) [Arrell et al., 2001]. This suggests the phosphorylation
of MLC-1 could be part of the molecular changes of preconditioning that can prevent
some of the damage from ischemia. Although there is evidence that ischemia itself does
not cause a change in phosphorylation. It has been displayed that in perfused heart fibers
there was 86.6 ± 2.5% unphosphorylated MLC-1 and ischemic fibers with 86.5 ± 2.9%
unphosphorylated MLC-1 [Han and Ogut, 2010]. As well as 76.3 ± 2.8%
unphosphorylated Myosin Light Chain-2 (MLC-2) in perfused fibers and 73.1 ± 2.7%
unphosphorylated MLC-2 in ischemic fibers [Han and Ogut, 2010]. Their data showed
no significant changes in light chain phosphorylation status in perfused and ischemic rat
cardiac muscle fibers, which helped focus attention on the other sections of myosin that
may actually be modified.
Areas of mouse heart that were not part of the myocardial infarction site could
have protein modifications as well. These remote areas are part of the overall left
ventricular dysfunction, or decreased contractile function, brought on by localized
myocardial infarction. One study found the function of infracted heart myosin was
reduced 0.56 ± 0.11% (adjacent) and 0.60 ± 0.16% (remote) of the control [Rao et al.,
2007]. There was also only 85% of control velocity (control was 4.9 ± 0.2 um/s) in the
adjacent zone for moving filaments in vitro as well as a decrease in the number of actin
filaments bound to the motility surface, which was likely due to impaired actin-myosin
binding [Rao et al., 2007]. This study isolated identical myosin concentrations
(250ug/mL) from each muscle tissue area sampled to ensure that the number of myosin
on the in vitro surface was not the reason for the decreased function and velocities found
in both the adjacent and remote areas [Rao et al., 2007].
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Myosin was analyzed by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel
electrophoresis) and stained with 5-IAF (a fluorescent dye) showed that there was a 25 ±
1% decrease in reactive cysteine-sulfhydryls in the remote zone compared to the control,
which meant that some available reactive cysteines were oxidized [Rao et al., 2007].
Alterations to one of these reactive cysteines could possibly have led to unfolding of the
protein and thus a loss of function. Also SDS-PAGE showed no cardiac myosin isoform
changes [Rao et al., 2007]. This experiment allowed one to theorize that left ventricular
dysfunction in the remote area after a myocardial infarction may be due to some type of
modification to myosin. The myosin dysfunction may have been caused by oxidative
stresses that lead to modifications of the heavy chain or myosin binding protein-C [Rao et
al., 2007]. Another study displayed that ONOO- inhibited the S1 actin activated ATPase
rate up to 50% and that ONOO- likely oxidized the reactive cysteines (C707 and C697)
on Myosin S1 fragment, which could also cause the protein to partially unfold and thus
increase access for protease degradation [Tiago et al., 2006]. This degradation could be
due to the activity of matrix metalloproteinase-2, which normally acts outside the cell,
but has been shown to cleave MLC-1 and result in altered cardiac function in vitro
[Sawicki et al., 2005]. Inhibiting matrix metalloproteinase-2 reduced cleavage of
proteins from IR (specifically MLC-1 was identified by mass spectrometry). MLC-1 can
be another target for matrix metalloproteinase-2 and this cleavage may lead to the
reduced cardiac function post IR [Sawicki et al., 2005].
Possible Troponin Alterations
Alterations to Tn are one of the most likely reasons for the decreased contractile
function post-ischemia. In an in vivo permeabilized fiber study of rat cardiac muscle,
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specifically the anterolateral papillary, it has been shown that there are changes in
phosphorylation of two subunits of Tn (TnI and TnT) [Han and Ogut, 2010]. A ligature
was secured on one of the left coronary arteries, which restricted the blood flow for 30
minutes (ischemia), and then it was removed to allow reperfusion for 60 minutes.
Ischemia and reperfusion treatment resulted in reduced force and Ca2+ sensitivity
accompanying a loss of maximal force, an increased Ca2+ EC50 (Ca2+ concentration
needed to achieve the half maximal force), and a clear reduction in stiffness [Han and
Ogut, 2010]. A 2-dimensional SDS-PAGE was used to determine if TnT was either
mono or bis-phosphorylated. It was discovered that perfused cardiac tissue contained
22.1 ± 2.2% mono-phosphorylated and 77.6 ± 2.3% bis-phosphorylated TnT [Han and
Ogut, 2010]. In ischemic fibers there was an increase of mono-phosphorylated-TnT to
39.6 ± 3.0% and a decrease of bis-phosphorylated-TnT to 60.3±2.9% [Han and Ogut,
2010]. Also the phosphorylation of Ser23/24 on TnI of perfused cardiac muscle was
discovered to be 100 ± 7.4% and this decreased to 65.9 ± 16.2% in ischemic fibers [Han
and Ogut, 2010]. This suggests that myosin is unlikely to be the cause for decreased
cardiac muscle function, but the thin filament regulation is very likely to have several
modifications that can result in altered function [Han and Ogut, 2010]. The reduced
initial attachment rate found in the ischemic tissue displayed that the Ca2+ controlled thin
filament activation was likely the causal element [Han and Ogut, 2010]. The TnT
dephosphorylation could somehow influence the status of the thin filament and thus alter
the transition of crossbridges to and from attachment states. This data clearly implicates
TnT and TnI modification in controlling contractile capabilities.

18

Isolated Tn from end-stage failing and non-failing human hearts have also been
used in the regulated in vitro motility assay and functional changes occurred. Tn from
non-failing cardiac tissue at pCa5.4 displayed increases in thin filament (actin-Tm)
velocity after addition of Tn from both failing- and non-failing human hearts, however
the magnitude of velocity change was significantly larger with the non-failing heart Tn
(52 ± 4% ) than the failing-heart Tn (35 ± 2%) [Knott et al., 2002]. There was an
increased sensitivity to Ca2+ for the failing heart Tn as the EC50 for failing heart
decreased 1.76 ± 0.20 fold as compared to non-failing cardiac Tn and filament velocity
was also found to have decreased 1.89 ± 0.62 fold in the failing heart tissue [Knott et al.,
2002]. This data demonstrated that a functional alteration to Tn could affect Ca2+
sensitivity and contractile function of cardiac myofibrils.
In another study, low blood flow ischemia was performed for 3 days to the left
anterior descending artery in a murine model. Using phospho-specific antibodies it was
discovered that there may have been Ser23/24 and Ser43/45 phosphorylation changes on
TnI [Christopher et al., 2009]. This reduction of Ser23/24 phosphorylation on TnI had
been seen in other studies as well [Han and Ogut, 2010]. Additionally affinity
chromatography displayed that TnI had reduced affinity for TnC, which increased the
likelihood that modifications of TnI can contribute to reduced contractile function
[Christopher et al., 2009].
There are 2 isoforms of TnI in humans and there is a transition from ssTnI (slow
skeletal) expressed only in embryonic and neonatal hearts and cTnI (cardiac), which
replaces the embryonic isoform over time [Day et al., 2007]. They are 70% homologous,
but cTnI has a 32 amino acid sequence that can be targeted for phosphorylation by cAMP
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dependent protein kinase A and this phosphorylation site can lead to decreased Ca2+
sensitivity and cardiac myocyte relaxation [Day et al., 2007]. Also there has been a lot of
research displaying that TnI is cleaved by Ca2+ activated calpain (a proteolytic enzyme)
and can result in the decreased myofilament function [Day et al., 2007].
In addition, it has been shown that in an expressed truncated 1-192 cTnI mutant
there is an approximately 9 o shift towards the inner groove of the actin filament when
activated with Ca2+ alone [Galinska et al., 2010]. This shift in equilibrium (28 to 57%
enhanced C state) towards the open state would suggest that upon cleavage of the last 17
residues of cTnI there is an “enhanced C-state” that can increase the chance for myosin to
bind and thus allow for earlier activation of the filament (less Ca2+ needed i.e. increased
Ca2+ sensitivity) [Galinska et al., 2010]. Although this suggests that there is only a
difference when Ca2+ is bound as the frequency of the Tm occurring in the blocked state
remained virtually identical.
Possible Tropomyosin Alterations
Tm can be phosphorylated, which can affect the way the thin filament is regulated
and thus affect contractility. There can be a significant change in the phosphorylation
level in muscle tissue isolated from the area completely remote from a site of localized
infarction and the phosphorylation of Tm may be caused by oxidative stress from the
ischemic area [Rao et al., 2007]. Another experiment, which involved rabbit fast skeletal
leg muscles, displayed phosphorylation of alpha-alpha-Tropomyosin (αα-Tm) and TnT
[Heeley, 1994]. The five parts of striated muscle thin filaments (actin, Tm, TnT, TnC,
TnI) allow for Ca2+ controlled contraction activity and TnT actually binds to Tm at two
different sites. Different combinations of isomorphs of Tm and TnT can have different
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Ca2+dependent tension levels [Heeley, 1994]. The phosphorylation of Ser283 at site one
of Tm and phosphorylation of acetyl-Ser 1 of TnT can change Ca2+ related tension and so
the purpose of the study was to display the effects of in vivo modification on thin filament
function [Heeley, 1994]. Using fully phosphorylated αα-Tm, TnT, and T1 (T1 is a
fragment of TnT), it was discovered that phosphorylated Tm increased the activating
properties of the regulatory thin filaments [Heeley, 1994].
Fragment T1 had equal affinity to αα-Tm whether the Tm was phosphorylated or
not, but the TnT and phosphorylated αα-Tm affinity was stronger than the control
[Heeley, 1994]. With non-phosphorylated αα-Tm, T1 down regulated actin-activated
myosin-S1 ATPase activity and this displayed that T1 of the TnT protein has modulating
effects on this ATPase activity, although TnI bound to Tm had a more significant
reduction in ATPase activity and thus was likely a more important factor [Heeley, 1994].
Activation of myosin-S1 was twice as fast for phosphorylated αα-Tm regulated filaments
and yet there was never a significant effect from phosphate on acetyl serine 1 of TnT (or
fragment T1), which suggests that higher levels of phosphorylated Tm may actually be
able to produce more rapid contractions [Heeley, 1994].
Quantifying Post-Translational Modifications with Mass Spectrometry
High pressure liquid chromatography coupled with electrospray ionization tandem
mass spectrometry can determine the levels of post-translational modifications in protein
samples such as native thin filaments (NTF) [Previs et al., 2008]. Liquid chromatography
involves the separation of molecules via passing a sample in solution through a column
that has different affinities for certain functional groups or other characteristics of the
molecules. For our study we used hydrophobic interaction chromatography (HIC) and
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thus we used a column (C18) designed to interact with the hydrophobic residues in our
sample peptides [Weith et al., 2012]. During chromatography, a column is loaded with
the sample and then the solution is slowly changed over a gradient to allow proteins to be
separated slowly over time, which allows an undesired "void" volume to be washed out
of the column before the sample peptide.
During electrospray ionization, a high voltage current is applied to samples to
vaporize them into ions, which can then be separated by their mass-to-charge ratio via the
electromagnetic fields within the mass spectrometer. These ions can be quantified and the
ion profiles compared to a library of known protein products. The amount of
phosphorylation can be determined by comparing the ion currents from each desired
peptide sequence in a phosphorylated set to its dephosphorylated reference peptide using
a mass balance approach [Previs et al., 2008 , Weith et al., 2012]. Two sets, one with
and one without dephosphorylation by alkaline phosphatase, are required to quantify a
change to the peptides phosphorylation status. This is due to phosphorylation causing
mis-cleavage when near tryptic cleavage sites [Steen et al., 2005], which otherwise
would alter the results from the mass spectrometry.
Summary
Ischemia has been proven to induce a clear decrease in tension related to
decreased Ca2+ sensitivity, which implicates alterations to the cardiac regulatory proteins
as well as the myosin in terms of their interactions with actin. There are several damaging
compounds which can accumulate during periods of restricted blood flow and might
cause deleterious modifications to the regulatory proteins and possibly myosin as well.
For example myosin was found to have some reactive cysteines oxidized due to ischemia
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and any alterations to these areas could lead to a loss of function, but there are conflicting
data as to whether myosin is a primary cause of decreased function. Myosin binding
protein -C was also implicated, because it had an increase in carbonylation due to
oxidative stress in the tissues remote to localized heart tissue infarct correlated with
decreased function. Changes in phosphorylation status of TnI could be a key factor in
Ca2+ controlled actomyosin interaction, because of its interaction with TnC (the subunit
that binds Ca2+). Also Tm, from skeletal muscle, was found to have an increase in
phosphorylation, but dissimilar to Tn phosphorylation it produced more rapid
contractions.
Although there has been extensive research attempting to elucidate the factors that
cause changes in tension and contractile properties of post-ischemic cardiac tissue, there
is still no specific understanding of the direct mechanism of this change. There are many
leading theories involving oxidative damage or metabolite build up that could lead to
covalent modifications to regulatory proteins or to myosin itself and thus reduce force
production. The specific mechanism causing reduced Ca2+ sensitivity remains unknown,
but it may be that the Ca2+ binding subunit TnC loses affinity for Ca2+ upon direct
phosphorylation or phosphorylation of another subunit. Differences in animal models can
be especially important and thus porcine post-ischemic and reperfusion models should be
studied to understand tissues very similar to humans. One of the most important tools to
employ in these studies is the use of in vitro motility assays specifically designed to
examine the differences in post-ischemic and reperfused myosin and NTF (actin, Tn, and
Tm). The actual change to the actomyosin crossbridge cycle is also unknown and without
knowledge of the affected proteins it is difficult to pinpoint the specific alterations in the
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cycle. Mass spectrometry can accurately detect the post translational modifications to the
proteins and thus can suggest underlying mechanisms for observed functional changes. It
remains unanswered if there is permanent ischemia and reperfusion damage or if there
are therapies that can reverse the changes which occurred to the protein structures.
Research needs to be conducted to discover the protein alterations and thus the
mechanisms by which reduced left ventricle function occurs before more effective
treatments can be discovered.
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CHAPTER III
METHODS
Ischemia/reperfusion protocol
All surgical procedures involving animals were in strict compliance with the NIH
Guide for the Care and Use of Animals. The parent study from which the tissue samples
were obtained was IACUC-approved and conducted in a USDA certified laboratory.
Female domestic Yorkshire swine aged 3–4 months and weighing approximately 30–35
kg prepared as previously described [Mader et al., 2010], were used for the cardiac
arrest-resuscitation experiments. The three animals included in this substudy were part of
a larger study involving 80 animals, 45% of which attained ROSC. During the protocol
the animals were sedated with intramuscular telazol (5 mg/kg), ketamine (2.5 mg/kg),
and xylazine (2.5 mg/kg). Isoflurane was provided to facilitate endotracheal intubation
and intravenous (IV) access. The inhalation anesthetic was then discontinued and a
surgical plane of anesthesia was achieved using an IV propofol bolus (2 mg/kg) followed
by a continuous infusion (80 mcg/kg/min) titrated to effect. The animals were ventilated
with room air, using a volume-cycled ventilator adjusted the tidal volume and ventilatory
rate to maintain eucapnea. A nasopharyngeal probe was placed through the oral cavity
into the animal's esophagus to measure core body temperature. Three surface electrodes
configured to correspond to a standard lead II electrocardiogram (ECG) surface
electrodes were secured to the proximal forelimbs and thorax.
Neuromuscular paralysis was induced with pancuronium (4 mg initial bolus IV)
and an arterial introducer (8.5 Fr) was placed into the right femoral artery and a venous
introducer (8.5 Fr) into the right femoral vein under direct visualization. Micro–
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manometer tipped pressure catheters (Mikro-Tip, Millar Instruments, Houston, TX) were
placed into the ascending aorta and right atrium. Arterial blood gas was obtained as soon
as access was established and just prior to ventricular fibrillation induction. All central
vascular access ports were connected to a pressurized liter bag of normal saline
containing heparin. The ECG tracing, as well as the arterial and venous pressures were
monitored and recorded continuously throughout the experiment (PowerLab M8/30, AD
Instruments, Colorado Springs, CO). Immediately before induction of ventricular
fibrillation, a 2-mg bolus of pancuronium was given, the propofol infusion was
discontinued, and the ventilator was disconnected.

Figure 5. Global ischemia protocol. Ventricular fibrillation was induced as previously
described [Mader et al., 2010] with a transthoracic current (100mA at 60Hz) and was
untreated for 12min. ventricular fibrillation lasted for 4min before complete electrical
failure was reached (green bar) at which point circulation stopped completely (yellow
bar) and finally metabolic failure was reached at ~10min. (pink bar). Resuscitation efforts
began 12min after induction of ventricular fibrillation, initially with manual chest
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compressions (MCC) and infusion of epinephrine (drug, 0.1mg/kg). At minute 15 we
attempted to restart circulation electrically (RS1) and at 18min. If ROSC it was
maintained for 2hrs and then the animals were sacrificed and cardiac muscle samples
were taken from the left ventricle (IR2). If ROSC was not restored then after 20min
cardiac muscle samples were taken from the LV (IDNR). Control animals were prepared
identically but did not receive the ischemia protocol (Control). “ˆ” Indicates when a drug
was administered.

Global ischemia and the resuscitation protocol were performed as previously
described [Mader et al., 2010]. Briefly, ventricular fibrillation was induced by a 3-s, 60Hz, 100-mA transthoracic alternating current. At minute 12 of untreated ventricular
fibrillation, dynamic baseline characteristics were again recorded and resuscitation was
attempted beginning with mechanical chest compressions using an oxygen-powered
mechanical resuscitation device (Life-Stat Mechanical CPR System, Michigan
Instruments, Grand Rapids, MI) that provides standardized closed chest compressions in
the anterior-posterior direction at a rate of 100/min. The device was programmed to
deliver chest compressions and ventilation (Vt = 500 cc, Fi02 = 100%) in a ratio of 30:2.
The animals were resuscitated using a standard combination of resuscitation drugs
[Fig 5]. Attempted resuscitation was terminated after the ROSC or 20 min of failure.
Animals attaining ROSC were immediately placed back on the ventilator, a low dose
propofol infusion was restarted and titrated to optimize the effect, and norepinephrine
was given intravenously to maintain a systolic blood pressure above 80 mm Hg for 2 h.

27

At the conclusion of each experiment, the hearts were immediately excised, diced, and
put into liquid nitrogen. The samples were kept on dry ice during transport and stored in a
−80°C freezer.
Cardiac tissue samples were obtained from porcine hearts that underwent one of
three conditions: (1) samples from a control animal that was subjected to the surgery but
that did not experience cardiac arrest or subsequent resuscitation and reperfusion
(control); (2) from an animal subjected to 12 min of global ischemia and attempted
resuscitation for 20 min that included epinephrine (0.01 mg/kg), vasopressin (0.5 U/kg),
amiodarone (4 mg/kg), sodium bicarbonate (1.0 mEq/kg), and metoprolol (0.2 mg/kg) but
spontaneous circulation failed to return (IDNR); and (3) from an animal that underwent
12 min of global ischemia and successful resuscitation after epinephrine (0.01 mg/kg),
vasopressin (0.5 U/kg), amiodarone (4 mg/kg) on the third defibrillation attempt,
followed by 2 h of sustained reperfusion (IR2).
Proteins
Cardiac myosin was isolated from porcine ventricular tissue based on a method
previously established for mouse cardiac tissue [Tyska et al., 2000]. The purification of
the myosin molecules involves the manipulation of salt concentration of the extraction
solution, which at low salt the myosin monomers form filaments that can allow them to
be isolated from the other tissue proteins by ultracentrifugation. Briefly a 2-mL aliquot of
extraction buffer (300 mM KCl, 150 mM PO4, 20 mM EDTA, 5 mM MgCl2, pH 6.7, 3.3
mM ATP, and 5 mM DTT) was added to ~400 mg of porcine cardiac tissue and
continuously homogenized for 12 minutes in a 2mL dounce homogenizer. The dounce
was chilled prior to introduction of the tissue as well as kept submerged in ice for the
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majority of the 12 minutes of homogenizing. The solution was then centrifuged (5
minutes; 10,000 g; 4 °C) to pellet insoluble tissue and the supernatant was centrifuged
once more for 20 minutes at 400,000 g to remove any filamentous proteins. The myosin
containing supernatant was then precipitated by 10-fold dilution with ddH2O for 60
minutes and then centrifuged for 10 minutes at 10,000 g, and 4 oC. The supernatant was
discarded and the myosin pellet was gently rinsed with cold ddH2O. The pellet was
homogenized in a minimum volume of a high salt buffer (25 mM Imidazole, 600 mM
KCl, 1 mM EGTA, 4 mM MgCl2, pH 7.4) and the concentration determined with a
spectrophotometer (extinction coefficient of 0.55, [Margossian and Lowey, 1982]).
An additional purification was performed on a subset of the cardiac myosin using
HIC as previously described [Malmqvist et al., 2004] with minor modifications. Briefly,
the isolated myosin was first dialyzed overnight at 4 °C against 1.45 M ammonium
sulfate (AmSO4) and then centrifuged (15 minutes; 10,000 g) to remove any aggregating
proteins. The supernatant was loaded on to the HIC column (5 mL Toyo pearl ether650M, Tosoh Biosciences Inc., Grove City, OH) at 1.45 M AmSO4. The AmSO4 was
reduced to 1.2 M causing the elution of the purified myosin, following a collection of
proteins that weakly interacted with the column (Figure 7 shows chromatograph and gel).
NTF were isolated using an established protocol [Lehman et al., 1995], in which
~200 mg of tissue was exposed to thin filament extraction buffer (25 mM imidazole, 1
mM EGTA, 100 mM KCl, 4 mM MgCl2, 5 mM ATP, 10 mM DTT, pH 7.0) and
homogenized for 12 min on ice (0°C). The homogenate was initially centrifuged (10,000
g, 4°C) for 5 min followed by a second centrifugation (40,000 g, 4°C) of the supernatant
for 20 min to remove myosin and any bulk tissue. Subsequently, the supernatant was kept
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and centrifuged (200,000 g, 4°C) again for 45 min to pellet the thin filaments which were
re-suspended in 300 μL of thin filament extraction buffer before a final clarification spin
(40,000 g, 4°C) for 5 min to remove any remaining myosin. The supernatant was kept
and then a final centrifugation was performed for 45 min at 200,000 g to collect the thin
filaments. The resultant pellets were brought up in an extraction buffer (7.0 pH, 25 mM
imidazole, 1 mM EGTA, 100 mM KCl, 4 mM MgCl2, 10 mM DTT) labeled
tetramethylrhodamine isothiocyanate-phallodin (TRITC-phallodin) (Sigma-Aldrich Inc.,
St. Louis, MI) at a 1 μM. Chicken skeletal actin was also used to assess the cardiac
myosin function and it was isolated from pectoralis muscle and fluorescently labeled with
TRITC-phallodin.
Solutions
The pH of each buffer was determined by a Fisher Scientific pH-meter, which
was calibrated prior to determining the pH of each solution. Sodium hydroxide (NaOH)
was used to increase the pH of each motility solution and hydrochloric acid (HCl) was
used to decrease it.
Immediately prior to beginning a motility experiment, the myosin was further
purified by removing myosin heads that were trapped in a rigor state and thus inactive.
This involved the addition of filamentous chicken skeletal actin and 2mM ATP and
centrifugation at 400,000g for 20 minutes at 4°C. After which the supernatant was
introduced into the flow cells in the motility assay. The rigor-like myosin heads would
remain bound to the filamentous actin in solution, but the functional myosin heads would
hydrolyze the ATP, separate from the filamentous actin, and would remain in the
supernatant solution.
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In vitro motility
Flow cells were used to inject different elements that were needed to simulate
physiological environments and to study the motility of molecular motor proteins. This
involves nitrocellulose coated coverslips glued onto a glass slide with enough space for
the injection of solutions. The technique was created to view moving fluorescent actin
filaments in the presence of ATP on a bed of myosin, which is affixed to glass [Kron and
Spudich, 1986]. The flow cell temperature was maintained at 30o C with an objective
temperature controller collar.
The impact of the ischemia/reperfusion of contractile protein function was
assessed using the in vitro motility assay using previously established methods [Debold et
al., 2011 , Debold et al., 2012]. Briefly, 60uL of isolated myosin (in a high salt buffer:
300 mM KCl, 25 mM Imidazole, 1 mM EGTA, 4 mM MgCl2, pH 7.4, 10 mM DTT) was
adhered to a nitrocellulose coated microscope coverslip as part of a flow cell at 200ug/ml
and incubated for 30 seconds. 60uL of bovine serum albumin (BSA) (0.5mg/mL) was
then added to cover any areas of the surface not coated by myosin and allowed to
incubate for 60 seconds. Then 60uL of actin coat (actin that had been put onto a vortex
mixer to ensure only small actin filaments would be present for the myosin heads to bind
to) in the absence of ATP, was injected into the flow cell and incubated for 30 seconds.
40uL of ATP wash was injected into the flow cell and then incubated for 30 seconds,
which was repeated immediately after the initial incubation for a total of 80uL. This
allowed all functional myosin heads to release the small actin coat pieces. 40uL of
TRITC-labeled NTF (5nM in actin buffer) was then injected and incubated for 60
seconds, which was repeated immediately after the initial incubation for a total of 80uL.
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Then 60uL of actin buffer was flowed through the cells, which maintained a low salt
environment for the actin. 60uL of the final motility buffer was added to the chamber (25
mM KCl, 25 mM Imidazole, 1 mM EGTA, 4 mM MgCl2, pH 7.4, 2 mM ATP, 10 mM
DTT, with an amount of CaCl2 required to achieve the appropriate free [Ca2+]), which
also contained an oxygen scavenging system (glucose, glucose oxidase, and catalase) to
slow photo-bleaching of the fluorescently labeled actin filaments.
The flow cells were then loaded onto a Nikon Eclipse Ti inverted microscope
with a 100X, 1.4NA CFI Plan Apo objective and the fluorescent actin filaments were
visualized by an ICCD camera (Stanford Photonics, Inc., Palo Alto, CA). The video was
captured by an Epix-LVDS frame grabber (Epix, Inc., Buffalo Grove, IL) coupled to the
ICCD camera. Piper ControlTM 2.5 software (Stanford Photonics, Inc. Palo Alto, CA) was
used to capture three to four video fields for each flow cell at 10 frames s-1 for 30
seconds. The filament motions were manually tracked using the MtrackJ [Meijering et
al., 2012] plugin for ImageJ [Abramoff et al., 2004]. The percentages of filaments
moving were calculated via an ImageJ plug-in called wrMTrck [Nussbaum-Krammer et
al., 2015]. 4-5 motility experiments were conducted each using fresh isolations for both
myosin and thin filaments for each condition.
Differences in naked skeletal actin and NTF velocities among each condition
were determined using a One-Way ANOVA followed by a Tukey’s HSD post hoc. To
determine the Ca2+ sensitivity of the NTF, their velocities as a function of the –log of the
Ca2+ concentration (pCa) were fitted to the Hill equation:
V = Vmax/(1 + 10n(pCa50 –pCa))
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using SigmaPlot R 11.2 (Systat Software, San Jose, CA). The hill equation derived the
Ca2+ concentration required to elicit half maximal filament velocity (pCa50) and the Hill
coefficient (n) to gain insight into the cooperative behavior of activation.
Mass Spectrometry
In preparation for mass spectrometry denaturing SDS-PAGE was conducted with
precast 12% bis-Tris polyacrylimide gels (BioRad, Life Science Research, Hercules,
CA). The identified bands were excised from the gel, cut into small cubes, and placed
into Eppendorf tubes. Residual stain and excess water was removed with a 50%
acetonitrile solution and the gel slices were dried in a speed vacuum device as previously
described [Previs et al., 2012]. Next, one set of samples was rehydrated with 8 μL of
alkaline phosphatase (Sigma–Aldrich Inc., St. Louis, MI) in 92 μL of ammonium
bicarbonate and incubated for 18 h at 30°C, allowing the phosphatase to thoroughly
impregnate the gel and dephosphorylate the protein samples. The samples were dried via
a speed vacuum device and subsequently rehydrated with 2 μg of trypsin (Promega,
Madison, WI) in 100 μL of ammonium bicarbonate and incubated for 18 h at 37°C. After
18 h of incubation 7 μL of 90% formic acid was added to deactivate the trypsin. The
resultant peptides were extracted with 25 mM ammonium bicarbonate/50% acetonitrile
solution, dried in a speed vacuum device, and reconstituted in 0.05% heptafluorobutyric
acid.
Electrospray ionization liquid chromatography tandem mass spectrometry (LCMS) was carried out in data dependent mass spectrometry mode using an LTQ ion trap
mass spectrometer (Thermo Electron Corporation) coupled to a 1 mm C18 column as
previously described [Weith et al., 2012]. Initial SEQUEST searches were performed to
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identify peptides using the IPI human protein sequence database (v3.75) downloaded
from the EMBL- EBI website. Subsequent searches only contained the pig cardiac TnI
(A5X497) and pig α-Tm (P42639) sequences downloaded from UniProtKB. The degrees
of site-specific TnI and α-Tm phosphorylation and truncation of the C-terminus of TnI
were determined from the extracted ion currents for specific peptides of interest in the LC
chromatograms using label free-proteomic strategies as described in the Results Section.
Phosphorylation levels were determined using each of the five reference peptides listed
for TnI and α-Tm in the Results Section in three samples from each group, before and
after treatment with alkaline phosphatase. Statistical significance was determined from
the individual measurements from each reference peptide using a Student's t-test.
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CHAPTER IV
RESULTS
Changes to Contractile Protein Function
Cardiac myosin’s ability to translocate actin filaments in vitro was not
significantly different in samples that underwent either ischemia with (IR2) or without
reperfusion due to failed resuscitation (IDNR) [Fig 6]. This indicated that the
ischemia/reperfusion protocol may not have had an effect on the myosin’s function.

Figure 6. Effect of ischemia/reperfusion on Vactin. Means ± SEM for unregulated (no
Tn/Tm) actin filament velocities in the in vitro motility assay using myosin isolated from
the corresponding condition. The myosin used was isolated from tissue from control,
ischemia with 2 hours of reperfusion (IR2), and ischemia without resuscitation (IDNR).
Data were analyzed using a Kruskal-Wallis ANOVA, but all comparisons were nonsignificant (p>0.05).
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Figure 7. Representative chromatograph from myosin purification over an HIC
column. The isolated myosin from porcine myocardium was additionally purified using
HIC based on a previously described methodology [Malmqvist et al., 2004] with minor
modifications (see Methods). Chromatograph displays absorbance at 280nm vs. elution
volume. Proteins with minimal affinity for the column elute at high (1.45M) AmSO4
(first broad peak). After the AmSO4 is reduced to 1.2M myosin is released (large narrow
peak). This process removed impurities including actin and likely Tm, selecting for
myosin and its light chains (Essential Light Chain, Regulatory Light Chain) as shown by
SDS-PAGE gel (inset).
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Figure 8. Purification with HIC column enhances Vactin. Further purification of the
myosin using an HIC column nearly doubled Vactin from both Control tissue and tissue
exposed to ischemia with 2 hours of reperfusion (IR2) (P<0.001). However, there was no
difference between conditions with either the isolated myosin or the HIC purified
myosin.

Cardiac myosin was purified via an HIC column as it may be less stable than
skeletal myosin and possibly the ischemia increased this instability. Control and IR2
myosin samples were run over the column [Fig 7] and the resultant data displayed that
the purification enhanced velocity to nearly double the velocity of both samples [Fig 8].
However, both samples were improved and were not significantly different from each
other, which suggests that the column likely removed impurities and myosin that poorly
hydrolyzes ATP [Malmqvist et al., 2004] in earlier peaks than the eluted myosin sample.
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The proteins eluted before the myosin sample were present in all samples, but the
quantity was not affected by the ischemia/reperfusion protocol. It appeared that myosin’s
function in the in vitro motility assay was unaffected by our model of
ischemia/reperfusion.

Figure 9. Effect of ischemia/reperfusion on NTF velocities (VNTF). Means ± SEM for
native thin filament velocities in the in vitro motility assay using myosin isolated from
the control tissue sample. The NTF used was isolated from control, ischemia with 2 h of
reperfusion (IR2), and ischemia without resuscitation (IDNR). Data analyzed using a
non-parametric Kruskal–Wallis ANOVA and indicated that IDNR was significantly
greater than control velocity *, (p < 0.05). The data represent the average actin filament
velocities from 20 to 30 s videos from Control, 19 from IR2 and 16 from IDNR.
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Regulatory proteins may be vulnerable during ischemia [Gao et al., 1997 ,
McDonough et al., 1999] and so we determined the velocity of these NTF isolated from
each condition. At pCa 4 control and IR2 NTF samples had identical velocities [Fig 9 ,
Fig 10], however IDNR samples moved significantly faster at 25% (p<0.05) greater than
the control value [Fig 9]. The increased average velocity cannot be due to a decrease in
moving filaments, because the percentage of moving filaments was similar for each
condition. This suggests that the IDNR condition had some modification to the regulatory
proteins Tn/Tm that regulate myosin’s interaction with actin
This regulation is Ca2+ dependent, so one can measure the velocity as a function
of Ca2+ and so we determined the Ca2+ sensitivity [Fig 10], which was plotted as the
concentration of free Ca2+in solution expressed as pCa. The IDNR NTF sample had a
significantly increased Ca2+ sensitivity (pCa50 6.57±0.04) compared to the control
(6.34±0.07) and IR2 (6.47±0.13) [Fig 10A , Table 1]. pCa50 is a measure of the Ca2+
concentration required to achieve half maximal activation of the filament and the IDNR
sample had an increased pCa50, because it activated at a lower Ca2+ concentration than
the other 2 samples and thus is more “sensitive” to [Ca2+]. Although not statistically
significant, the Hill coefficient was increased in IDNR samples, which suggested the
myosin and IDNR NTF sample seemed to have more cooperative binding compared to
control filaments. A higher Hill coefficient suggested that there is a cooperative
relationship between the binding of the ligand (exposed myosin binding site on actin) and
its enzyme (myosin) and a subsequent increase in the affinity of the enzyme for the
ligand (increased likelihood of a separate myosin molecule to interact with actin). We
then used quantitative mass spectrometry to determine what structural modifications may
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have occurred to Tn or Tm to induce this significant functional change only in the IDNR
sample.

Figure 10. Velocity-pCa data. A, NTF velocity (VNTF) plotted as a function of free
[Ca2+] in –log units (pCa). Thin filaments from Control tissue are plotted with filled black
dots and solid line, IR2 thin filaments with gray diamonds and solid gray line and the
filaments from IDNR are plotted with dark gray boxes and a dashed gray line. Points
represent mean ± SEM and the data were fit with the Hill equation (see Methods). *
indicates significantly (p<0.05) different from WT VNTF. B, percentage of NTF moving
as a function of free [Ca2+] symbols and lines same as in A. C, Motility index, defined as
the product of VNTF and percent moving plotted as a function of free [Ca2+].
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Table 1. Parameters for velocity-pCa fits to the Hill eq. VNTF indicates NTF velocities
for filaments isolated from non-ischemic control, ischemia followed by 2 hrs of
reperfusion (IR2) and ischemia followed by failed resuscitation (IDNR). n represents the
Hill coefficient. Values represent mean ± SEM. * indicates significantly (p<0.05)
different from Control tissue.

No Truncation of Troponin I
One of the most frequently observed structural changes associated with ischemia
is the proteolytic cleavage of the C-terminal end of TnI [Westfall and Solaro, 1992 ,
Gao et al., 1997 , van Eyk et al., 1998 , McDonough et al., 1999 , van Eyk and
Murphy, 2001]. We therefore used a mass spectrometry based, mass-balance approach to
determine if the C-terminus of TnI was truncated during ischemia. We measured the
relative abundance of the sum of the C-terminal 195NIDALSGMEGR205 (m/z = 581.78)
and 195NIDALSGm*EGR205 (m/z = 589.77) peptides in the control and experimental
samples that would be removed by ischemia induced proteolytic cleavage. The area under
the LC peak for the C-terminal peptide was normalized using the TnI reference peptides
used for the quantification of phosphorylation. The abundance of the C-terminal peptide
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did not differ for either group [1.09 ± 0.19 (IR2), 1.06 ± 0.26 (IDNR)] when compared to
controls. This lack of difference suggests that the C-terminus of TnI was not truncated as
a result of the ischemic treatments employed in the present study.
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Figure 11. LC elution profiles and data dependent MS2 spectra for TnI peptides. A,
Representative LC elution profiles for the non-phosphorylated 23SSANYR28 (red),
mono-phosphorylated 22RSSpANYR28 (grey) and bis-phosphorylated
21RRSpSpANYR28 (black) peptides. Data dependent MS2 spectra for the B, monophosphorylated 22RSSpANYR28 and C, bis-phosphorylated 21RRSpSpANYR28
peptides showing fragment ions used for peptide identification and localization of
phosphate.

Quantification of Phosphorylation
Peptides containing phosphate including: the mono-phosphorylated
22RSSpANYR28 (m/z = 467.20R) and bis-phosphorylated 21RRSpSpANYR28 (m/z =
585.23) peptides coming from TnI [Fig 11]; and 269AISEELDHALNDMTSpI284 (m/z =
919.89), 269AISEELDHALNDm*TSpI284 (m/z = 927.89), and
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269AISEELDHALNDm^TSpI284 (m/z = 935.89) peptides coming from α-Tm were
identified in the data dependent MS2 spectra and manually confirmed [Previs et al., 2008
, Weith et al., 2012]. (It should be noted that Sp represents phosphoserine and m* and
m^ denote methionine sulfoxide and sulphone). The degree of phosphorylation at these
sites was determined via a mass-balance approach [Previs et al., 2008 , Weith et al.,
2012] from the abundance of the non-phosphorylated analogues of these phosphopeptides
in each sample prior to and after the removal of phosphate with alkaline phosphatase. The
non-phosphorylated analogues were the properly cleaved 23SSANYR28 peptide and the
sum of the ion currents for the 269AISEELDHALNDMTSI284,
269AISEELDHALNDm*TSI284 and 269AISEELDHALNDm^TSI284 peptides.
Whereas this mass-balance approach is an indirect way to measure phosphorylation
levels, it provides accurate quantification of the fraction of the protein molecules in a
sample which are phosphorylated and obviates problems with quantification arising from
mis-cleavage when the phosphate is proximal to the tryptic cleavage site [Previs et al.,
2008]. For quantification, measured ion currents corresponding to peptides of interest
were extracted from the LC chromatogram and the area under each LC peak was
normalized using reference peptides within each sample to account for difference in the
total amount of protein loaded onto the gel [Previs et al., 2008 , Weith et al., 2012].
The area under each LC peak for the TnI peptides of interest were normalized using the
YDVEAK(m/z = 362.67), KLQLK (m/z = 629.43), ETLDLR (m/z = 746.40),
NITEIADLNQK(m/z = 629.83), and IFDLR (m/z = 332.19) peptides; and the area under
each LC for α-Tm peptides of interest were normalized using the HIAEDADR(m/z =
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463.72), SLEAQAEK (m/z = 438.22), IQLVEEELDR (m/z = 622.33), LVIIESDLER
(m/z = 593.83), and SIDDLEDELYAQK(m/z = 769.86) peptides as references.

Figure 12. Quantification of TnI and α-Tm phosphorylation. A, Percent
phosphorylation of TnI serines 23 and/or 24 and Tm serine 283 in NTF isolated from
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control hearts, and hearts following global ischemia that did not survive attempted
resuscitation (IDNR) or survived and were then subject to 2 hours of reperfusion (IR2).
B, Levels of mono- (serine 24) and bis-phosphorylated (serines 23 and 24) TnI relative to
the control. * p < 0.01 relative to control and ^ p < 0.01 relative to IDNR.

The overall percent phosphorylation of both TnI at serines 23/24 and αTm at
serine 283 was significantly enhanced with respect to the control [Fig 12A] in samples
from successful resuscitation followed by 2 hours of reperfusion (IR2). In contrast, the
overall levels of TnI and Tm phosphorylation of samples from the failed resuscitation
(IDNR) did not significantly differ from the control samples [Fig 12A]. However, this
method of quantification is not sensitive to changes in site-specific phosphorylation when
multiple phosphorylation sites are located within a single peptide, as was the case for TnI
serine 23/24. Therefore, we determined if there was a shift in the phosphorylation profile
between the mono- and bis-phosphorylated states by calculating the relative abundance of
the mono-phosphorylated 22RSSpANYR28 and bis-phosphorylated 21RRSpSpANYR28
peptides in each sample [Fig 12B]. We observed significant reductions in the abundance
of the mono-phosphorylated peptides (0.27 ± 0.10 (IR2) and 0.19 ± 0.04 (IDNR)) and
corresponding increases in the abundance of the bis-phosphorylated peptides (4.2 ± 1.3
(IR2) and 2.8 ± 0.7 (IDNR)) with respect to the controls following the bout of ischemia
regardless of survival [Fig 12B]. Therefore, under both ischemic conditions we observed
in increase in the relative abundance of the bis-phosphorylated TnI 21RRSpSpANYR28
peptide with respect to the control.
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CHAPTER V
DISCUSSION
In vitro Function of the Contractile Proteins
This study attempted to discover what structural and functional effects occurred to
the major contractile proteins following global myocardial ischemia and reperfusion. The
in vitro motility assay revealed no difference in labeled actin filament velocity for cardiac
myosin samples in either IR2 or IDNR conditions compared to the control [Fig 6]. As
there was no difference in myosin’s ability to translocate actin, any modifications present
were unlikely to have caused the depressed function others have seen in different studies.
Thus no further experiments were performed to determine if there were any structural
modifications to myosin. Other studies have used different ischemia paradigms, such as
ligation of blood vessels inducing local ischemia, which has been shown to cause
modifications by the production of ROS during ischemia [Zweier et al., 1989]. The ROS
can cause modifications to contractile proteins [Bolli and Marban, 1999] and affect
myosin’s ATPase [Tiago et al., 2006] and the ability to produce force in vitro and
translocate actin [Rao et al., 2007]. Other studies also employed longer periods of
ischemia (up to 60 minutes) and subsequent reperfusion of the heart for 24-72 hours. The
different protocols for inducing ischemia, as well as the durations of induced ischemia
and reperfusion could be the reason for the lack of observed changes to myosin. This
study had an ischemic bout of 12 minutes due to the rarity of the animal surviving a bout
longer than 15 minutes, which would not allow for any reperfusion due to a failure to
revive the animal (>50% fail to resuscitate) [Kern et al., 1996]. Others have studied the
heart in a Langendorff apparatus [van Eyk et al., 1998 , McDonough et al., 1999], but
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our study kept the heart in vivo during both the ischemic and reperfusion periods until
excision of the heart tissue upon conclusion of 12 minutes ischemia with or without
reperfusion. This short timeframe of 12 minutes applies more directly for the typical
timeframe of approximately 8 minutes for human cases of out-of-hospital sudden cardiac
arrest [Cobb et al., 1999]. A longer ischemic bout may lead to the changes other studies
have seen, but would likely not result in ROSC and not be relevant to real human
emergency cases with such rapid EMT unit response times.

Modifications to the Regulatory Proteins
Degradation of TnI is one of the most common modifications resulting from
ischemia/reperfusion especially in localized ischemic episodes, but we did not observe
any significant TnI degradation in this study. Proteolytic cleavage of TnI’s C-terminus
has been seen in many models and longer bouts of ischemia is positively correlated with
greater levels of cleavage [Gao et al., 1997 , McDonough et al., 1999 , Foster et al.,
2003 , Westfall and Solaro, 1992 , Day et al., 2007 , van Eyk et al., 1998 , Van
Eyk and Murphy, 2001]. This TnI truncation alters its ability to interact with TnC and
any alteration to this interaction can have drastic impacts on activation of the thin
filament, which has been suggested as part of ischemia-induced contractile dysfunction
[Gao et al., 1997 , McDonough et al., 1999]. This truncation may alter the muscle’s
ability to produce force and its Ca2+ sensitivity, which can lead to enhanced or even
diminished ability to respond to normal Ca2+ levels [Westfall and Solaro, 1992 , van
Eyk et al., 1998 , van Eyk and Murphy, 2001 , Foster et al., 2003 , Day et al.,
2007]. This cleavage, when severe enough, has been shown to influence the position of
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Tm on actin such that it increases the probability of myosin binding to actin [Galinska et
al., 2010]. SDS-PAGE staining was inconclusive (data not shown) and so mass
spectrometry was expected to have a greater resolution for detecting cleavage. Data
acquired via LC-MS suggested that there was no difference in TnI truncation between the
samples [Fig 11]. This lack of cleavage may also be attributed to the brevity of ischemia
in this study, because other studies with 15-60 minute ischemic bouts had increasing
amounts of truncation the longer the ischemia occurred [Westfall and Solaro, 1992 ,
Gao et al., 1995 , Gao et al., 1997 , van Eyk et al., 1998]. In addition, the type of
ischemia is important because artery occlusion is a more localized ischemia and removal
of the heart into a Langendorff apparatus is a different type of “global” ischemia for the
heart, because the whole heart is removed from the animal.
Previous studies suggested other common modifications such as oxidative
modifications, but there were no significant differences in oxidative changes to proteins
between any of the samples in our study (data not shown). However, we discovered that
there was an increase in bis-phosphorylation of Ser23 and 24 in both experimental
ischemia TnI samples [Fig 12B] and there was an increase in phosphorylation of α-Tm
only in IR2 pig samples [Fig 12A]. Unexpectedly, only the IDNR sample tissue resulted
in significantly altered thin filament Ca2+ sensitivity and maximal filament velocity [Fig 9
, Fig 10 , Table 1]. The increased maximal sliding velocities and Ca 2+ sensitivity seen
in IDNR samples occurred with only an increase in the bis-phosphorylation of TnI
Ser23/24, but this enhanced velocity was lost in the reperfused IR2 sample where there
was found to also be an increased level of α-Tm phosphorylation [Fig 12]. Other research
supports the possibility that phosphorylation of TnI may allow Tn to be more sensitive to
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Ca2+ and Tm phosphorylation can change the interaction of Tm monomers and thus
activation of the thin filament [Rao et al., 2009]. However, there are conflicting reports
of phosphorylation status of regulatory proteins after ischemia as some studies have seen
an increase in phosphorylation of TnI and α-Tm [Han and Ogut, 2010 , Han and Ogut,
2011] while other have found no change in PO4 [Rao et al., 2007].
Conclusion
This study was designed to elucidate the underlying structural and functional
changes to myocardial contractile proteins caused by global ischemia and reperfusion
injury due to sudden cardiac arrest. Our data contradicted the original hypothesis that
there would be a decrease of the in vitro velocity in samples that underwent
ischemia/reperfusion and that this would be due to post-translational modifications to
myosin with little or no damage to actin. There was no difference in sliding velocity for
across any of the samples when using cardiac myosin with unregulated actin [Fig 6 , Fig
8]. No mass spectrometry was performed because there were no functional effects
observed without using the NTF from the samples [Fig 6 , Fig 8]. There may have been
alterations to myosin, but in this case none that would be relevant to the scope of this
study.
Our original hypothesis predicted that ischemia/reperfusion would affect Ca2+
sensitivity of NTF due to cleavage/modifications of Tn. This hypothesis was determined
to be partly true, because the IR2 sample was not significantly different from control for
either myosin or NTF samples, however the IDNR NTF samples had a significant
increase in maximal sliding velocity and increase Ca2+ sensitivity [Fig 9 , Fig 10 ,
Table 1]. Also mass spectrometry was performed on regulatory proteins to quantify the
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amount of modifications that occurred to the proteins and the TnI in IDNR and IR2
samples had more bis-phosphorylated TnI compared to control, but only the IR2 sample
had an increase in Tm phosphorylation [Fig 12]. Our results agreed with the original
hypothesis as there was an increase in Ca2+ sensitivity that may have been due to an
increase in phosphorylation of TnI, but an unexpected increase in Tm phosphorylation
could have mitigated this increase. However, there was no significant cleavage of TnI,
although several previous studies have implicated this cleavage as a key player in
functional changes due to ischemia/reperfusion [Westfall and Solaro, 1992 , Gao et al.,
1997 , van Eyk et al., 1998 , McDonough et al., 1999 , van Eyk and Murphy, 2001].
One study had displayed that phosphorylating TnI with PKA then combining with the
rest of the filament proteins into reconstituted thin filament (RTF) increased Ca2+
sensitivity and velocity in the in vitro motility assay [Hunlich et al., 2005]. This supports
that TnI phosphorylation can alter velocity and Ca2+ sensitivity such as displayed in our
study, however there are inconsistencies across studies of whether TnI phosphorylation
increases or decreases velocity [Marston and de Tombe, 2008]. Our findings could
suggest that the changes in phosphorylation, increased Ca2+ sensitivity, and sliding
velocity may be due to a compensatory mechanism in the heart attempting to increase
contractility. This phosphorylation mechanism may adversely affect cardiac function
depending on the extent of this phosphorylation and which regulatory proteins are
affected.
Our findings were different when compared to several other studies likely due to
the different techniques, animal models, and timeframes employed for the experimental
ischemia/reperfusion. Acquiring more samples from different animals with varying
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ischemia/reperfusion times may have allowed us to determine the relation between the
duration of the ischemic event with the different modifications seen in other studies.
Another aspect not included in this study was investigating if there were alterations to the
thick filament. Studies have shown thick filament alterations can have affects as well,
such as phosphorylation of myosin binding protein-C, which is needed for proper cardiac
function and if altered could lead to certain cardiomyopathies [Sadayappan et al., 2005].
Different myosin binding protein-C phosphorylation states have been implicated in
altering Ca2+ sensitivity and maximal sliding velocities [Previs et al., 2012], loaded
shortening and power output [Korte et al., 2003], and also can be truncated during
ischemia similar to TnI [Sadayappan, 2012]. There can be many things that lead to
persistent contractile dysfunction and poor prognosis after ROSC following sudden
cardiac arrest, but this study displayed that there were post-translational phosphorylation
on muscle regulatory proteins that altered their function in vitro.
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